Analysts expect that Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) will announce sales of $919.03 million for the current quarter, Zacks Investment Research reports. Eight analysts have provided estimates for Alexion Pharmaceuticals’ earnings. The highest sales estimate is $936.00 million and the lowest is $904.62 million. Alexion Pharmaceuticals posted sales of $870.00 million in the same quarter last year, which would indicate a positive year over year growth rate of 5.6%. The business is expected to announce its next quarterly earnings report on Thursday, April 26th.
On average, analysts expect that Alexion Pharmaceuticals will report full year sales of $919.03 million for the current financial year, with estimates ranging from $3.91 billion to $4.28 billion. For the next financial year, analysts anticipate that the firm will post sales of $4.68 billion per share, with estimates ranging from $4.34 billion to $4.89 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Alexion Pharmaceuticals.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.39. The firm had revenue of $909.70 million during the quarter, compared to the consensus estimate of $880.38 million. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The business’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.26 EPS.
Shares of Alexion Pharmaceuticals (ALXN) traded up $5.67 during trading hours on Wednesday, reaching $125.68. The company’s stock had a trading volume of 2,638,278 shares, compared to its average volume of 2,000,000. The company has a market cap of $29,180.00, a P/E ratio of 57.92, a PEG ratio of 1.11 and a beta of 1.13. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.10 and a quick ratio of 2.62. Alexion Pharmaceuticals has a 52-week low of $96.18 and a 52-week high of $149.34.
In related news, EVP Julie O’neill sold 1,625 shares of the stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $119.83, for a total transaction of $194,723.75. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Ludwig Hantson sold 2,553 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total value of $310,521.39. Following the sale, the chief executive officer now directly owns 36,172 shares in the company, valued at approximately $4,399,600.36. The disclosure for this sale can be found here. Insiders have sold a total of 31,253 shares of company stock worth $3,656,229 in the last ninety days. Insiders own 4.35% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Xact Kapitalforvaltning AB lifted its holdings in Alexion Pharmaceuticals by 9.0% during the 4th quarter. Xact Kapitalforvaltning AB now owns 45,832 shares of the biopharmaceutical company’s stock worth $5,481,000 after purchasing an additional 3,789 shares in the last quarter. CNB Bank purchased a new stake in Alexion Pharmaceuticals during the 4th quarter worth about $150,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its holdings in Alexion Pharmaceuticals by 9.5% during the 4th quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 103,254 shares of the biopharmaceutical company’s stock worth $12,348,000 after purchasing an additional 8,997 shares in the last quarter. Delek Group Ltd. purchased a new stake in Alexion Pharmaceuticals during the 4th quarter worth about $10,291,000. Finally, Altman Advisors Inc. purchased a new stake in Alexion Pharmaceuticals during the 4th quarter worth about $1,599,000. 93.73% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Alexion Pharmaceuticals, Inc. (ALXN) Expected to Post Quarterly Sales of $919.03 Million” was first published by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3254179/alexion-pharmaceuticals-inc-alxn-expected-to-post-quarterly-sales-of-919-03-million.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.